SCHEDULE: Highbridge Capital Management Discloses Fortress Biotech Stake

Highbridge Capital Management, LLC has filed a Schedule 13G, reporting beneficial ownership of 7.8% of Fortress Biotech, Inc. common stock, primarily through warrants.

Summary

• Highbridge Capital Management, LLC (Highbridge) has filed an amendment to its Schedule 13G, indicating its beneficial ownership of Fortress Biotech, Inc. (the Issuer) common stock.
• The filing reports that Highbridge, acting as an investment adviser to certain funds and accounts (the Highbridge Funds), beneficially owns 2,734,654 shares of common stock.
• This ownership represents approximately 7.8% of the Issuer's class of common stock.
• The reported shares are issuable upon the exercise of warrants held by the Highbridge Funds.
• The filing specifies that Highbridge has sole voting power and sole dispositive power over these shares.
• The aggregate amount beneficially owned by Highbridge is 2,734,654 shares.
• The percentage of class is calculated based on 32,202,564 shares of Common Stock outstanding as of March 25, 2026, as reported in the Issuer's Annual Report on Form 10-K filed on March 31, 2026, and assumes the exercise of the warrants held by the Highbridge Funds.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial performance information about the company.

Positives

• Highbridge Capital Management, a significant investment entity, has disclosed a substantial stake in Fortress Biotech, Inc., potentially signaling confidence in the company's future prospects.
• The ownership is based on the exercise of warrants, which could indicate a strategic investment rather than a passive holding.

Negatives

• The filing does not provide specific financial performance data for Fortress Biotech, Inc., making it difficult to assess the underlying value of the investment from this document alone.

Risks

• The value of the reported shares is contingent upon the exercise of warrants, which may involve additional capital outlay and is subject to market conditions.
• The filing does not detail specific risks associated with Fortress Biotech, Inc.'s operations or the broader biotechnology industry.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Fortress Biotech, Inc. The future outlook for the reported shares is dependent on the performance of Fortress Biotech, Inc. and the terms of the warrants.

Industry Context

StockSavvy.ai notes that the biotechnology sector is characterized by high growth potential but also significant risk, often involving long development cycles and regulatory hurdles. Disclosures like this from investment managers can indicate strategic positioning within the sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Highbridge Capital Management may influence investor perception and potentially impact share price due to increased institutional interest.
• Creditors: No direct impact is indicated in this filing.
• Employees: No direct impact is indicated in this filing.
• Suppliers: No direct impact is indicated in this filing.
• Customers: No direct impact is indicated in this filing.

Next Steps

• Highbridge Capital Management will continue to monitor its investment in Fortress Biotech, Inc.
• Fortress Biotech, Inc. will continue its operations and report financial and operational updates as required.

Key Dates

Keywords

Fortress Biotech, Highbridge Capital Management, Schedule 13G, Beneficial Ownership, Warrants, Common Stock, Investment Adviser, SEC Filing, Biotechnology